The global anti-inflammatory drugs market constitutes various products such as oral and parenteral corticosteroids, NSAIDs, anti-inflammatory biologics, and immunosuppressants that are used for the treatment of inflammatory diseases including arthritis, spondylitis, colitis, and various other related conditions. Anti-inflammatory drugs act by blocking key inflammatory pathways in the body to inhibit inflammation progression and related symptoms. NSAIDs are among the most commonly prescribed anti-inflammatory medications and are available as prescription medicines as well as over-the-counter formulations. Biologics such as TNF inhibitors have revolutionized the treatment of rheumatoid arthritis and other autoimmune disorders.
The global Anti-Inflammatory Drugs Market is estimated to be valued at US$ 102248.44 Mn in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period from 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The rising prevalence of inflammatory diseases due to growing geriatric population and changing lifestyle factors is expected to drive the demand for anti-inflammatory drugs over the forecast period. It is estimated that by 2040, over 1.5 billion people will suffer from some form of arthritis globally. Moreover, factors such as increasing consumption of alcohol, tobacco, fast food, and physical inactivity have contributed significantly to the rising incidence of inflammatory diseases in recent years. This presents a lucrative growth opportunity for anti-inflammatory drug manufacturers.
The growing preference for biologics and targeted therapies over conventional drug options also acts as a key driver for the anti-inflammatory drugs market. Biologics have fewer side effects compared to corticosteroids and are highly effective for managing chronic inflammation, prompting more patients and physicians to opt for these newer treatment choices. This trend is expected to positively influence the demand for anti-inflammatory biologics in the coming years.
Segment Analysis
The anti-inflammatory drugs market can be segmented into corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and other drugs. The NSAIDs segment currently dominates the market and is expected to continue its dominance over the forecast period due to its affordability and easy availability over-the-counter (OTC). NSAIDs like ibuprofen and naproxen sodium are preferred for mild to moderate pain relief and are also effective in reducing inflammation and fever.
PEST Analysis
Political: Government agencies regularly monitor the safety and efficacy of anti-inflammatory drugs. Changes in healthcare policies and regulations can impact market dynamics.
Economic: Rising disposable incomes in developing nations are increasing healthcare expenditure and boosting market growth. However, pricing pressures and patent expiries are challenges.
Social: Growing geriatric population and increasing awareness about arthritis and other inflammatory conditions are driving demand. However, concerns remain regarding side effects of long-term usage.
Technological: Advances are increasing efficiency and specificity of new drugs while reducing side effects. Targeted delivery options are expanding treatment options.
Key Takeaways
The Global Anti-Inflammatory Drugs Market Growth is expected to witness high over the forecast period. The global Anti-Inflammatory Drugs Market is estimated to be valued at US$ 102248.44 Mn in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period from 2023 to 2030.
Regional analysis
The North American region is expected to maintain its dominance over the forecast period owing to the high per capita healthcare expenditure and growing geriatric population in countries like the US and Canada which are more prone to joint disorders.
Key players
Key players operating in the anti-inflammatory drugs market are Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Merck & Company, Inc., Novartis AG, Amgen, Inc., AstraZeneca plc, Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Biogen Inc., Sun Pharmaceutical Industries Ltd, Mylan, Inc., Aurobindo Pharma Limited, and Dr. Reddy€TMs Laboratories.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
